News

Gland Pharma has allotted 2,03,259 equity shares under ESOS on 02 June 2026. Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to Rs. 164,959,682/- comprising 164,959,682 equity shares of face value Re.1/- each.

Gland Pharma announced that the 48th Annual General Meeting(AGM) of the company will be held on 25 August 2026.

Gland Pharma announced that the Board of Directors of the Company at its meeting held on 15 May 2026, inter alia, have recommended the final dividend of Rs 20 per equity Share (i.e. 2000%) , subject to the approval of the shareholders.

Net profit of Gland Pharma rose 96.57% to Rs 366.68 crore in the quarter ended March 2026 as against Rs 186.54 crore during the previous quarter ended March 2025. Sales rose 22.31% to Rs 1742.79 crore in the quarter ended March 2026 as against Rs 1424.91 crore during the previous quarter ended March 2025.For the full year,net profit rose 47.07% to Rs 1027.32 crore in the year ended March 2026 as against Rs 698.53 crore during the previous year ended March 2025. Sales rose 14.50% to Rs 6430.65 crore in the year ended March 2026 as against Rs 5616.50 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales1742.791424.91 22 6430.655616.50 15 OPM %29.4424.39 -25.3422.59 - PBDT614.46384.09 60 1912.601440.53 33 PBT505.80288.33 75 1488.931062.66 40 NP366.68186.54 97 1027.32698.53 47 Powered by Capital Market - Live News

Gland Pharma will hold a meeting of the Board of Directors of the Company on 15 May 2026.